Sun Pharmaceutical declared its 2QFY05 results recently. The topline of the company grew by 10% while the growth in bottomline was 29% on a YoY basis. The improvement in bottomline was mainly due to a huge 490 basis points improvement in its operating profit margin in 2QFY05, on the back of savings made in raw material costs and other expenditure.
Operating Profit margin(%)
Profit before tax
Profit after tax
Profit after tax margin (%)
No. of shares
Earning per share*
Sun Pharma is a leading domestic pharma company with a strong presence in the lifestyle therapeutic segment. However, it started focusing in the exports market and in FY02 it acquired Caraco Pharma in the US. Further, it increased its stake in Caraco pharma in FY04 to 61% taking over majority control. With the help of its US subsidiary, the company has been able to grow its US business, which brings in synergies with Sun's business by backward integration in both manufacturing and R&D.
What has driven performance in 2QFY05?
Sales: Sun Pharma’s topline growth was fuelled by a strong performance in its formulations business, which recorded a 15% growth during 2QFY05. In the first half of FY05 the sales growth was 21% in formulations exports, which basically grew due to strong growth shown by Sun pharma's US based subsidiary Caraco Pharma. Caraco Pharma has shown a growth of 50% in the topline in the September quarter. However, revenues from the bulk drugs segment have slipped marginally due to the company's focus on formulations business. Sun Pharma’s core therapeutic segments of psychiatry, neurology, cardiology, diabetology, and gastroenterology, which make up for 70% of the domestic formulations sales, grew by about 12% as a whole during the quarter.
Grand Total ((A)+(B))
Operating margin: The operating margin of the company expanded by 490 basis points basically due to increased contribution from the exports business. With the company transferring Caraco pharma's manufacturing activities to the Indian plants, the company has been able to expand margins further. Despite a huge surge in R&D expenditure (8.2% of sales in 2QFY05), company managed to increase its operating profit due the savings in raw material costs and other expenditures.
Net Profit: The profit after tax has risen by 29% and the net profit margin expanded by 500 basis points. The major contribution to this expansion comes from improvement in its operating performance, however, lower tax charges due to increasing contribution from exports has also helped the cause.
What to expect?
At 462 the stock is trading at a P/E ratio of 22.4 times its annaulised 1HFY05 earnings. With its US subsidiary now turning profitable, the company is in a position to leverage its cost advantage in manufacturing and R&D by launching new drugs through Caraco Pharma in the US markets. Also, being a dominant player in the lifestyle segment in the domestic market, the company might see a good growth rate going forward as these segment are amongst the fastest growing therapeutic segments in the domestic market.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407